• GSK jilts Ionis rare disease drug as FDA filing nears fiercebiotech
    August 14, 2017
    GlaxoSmithKline has jilted Ionis Pharmaceuticals just before the pair was due to file for approval of inotersen. The action furthers recently installed GSK CEO Emma Walmsley’s plan to purge the Big Pharma of its rare disease programs.
PharmaSources Customer Service